Blood-Guided chemo dosing study for colon cancer withdrawn
NCT ID NCT06501989
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study aimed to see if adjusting the dose of the chemotherapy drug 5-FU based on its concentration in the blood could improve treatment for metastatic colorectal cancer. The study was withdrawn before enrolling any participants. It was designed for adults with metastatic colorectal cancer who had not received prior treatment for their metastatic disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Inova Health Care Service
Falls Church, Virginia, 22042, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?